Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Lewandowska (Warsaw, Poland), I. Beunders (Baden, Austria), M. Sterclova (Prague, Czech Republic), S. Majewski (Lodz, Poland), K. Gorska (Warsaw, Poland), B. Zolnowska (Warsaw, Poland), V. Muller (Budapest, Hungary), T. Peros-Golubicic (Zagreb, Croatia), S. Jimmy (Tel-Aviv, Israel), G. Wanke (Vienna, Austria), M. Vasakova (Prague, Czech Republic), J. Kus (Warsaw, Poland). Central European idiopathic pulmonary fibrosis (IPF) patients survey. 1314

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Lung function of idiopathic pulmonary fibrosis: Russian IPF registry (Moscow region) Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019 Longitudinal observation of idiopathic pulmonary fibrosis (IPF) patients cohort from one center in Poland. Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Registry of idiopathic pulmonary fibrosis patients Source: International Congress 2016 – Russia Session Year: 2016 The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Respiratory infections in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP) Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF) Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in Eastern Finland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013